The company showcased over 30 products targeting oncology, metabolic diseases, and autoimmune conditions. Among the drugs drawing significant attention were albumin-bound paclitaxel, bevacizumab, and semaglutide. Beyond current offerings, Kexing highlighted progress on several experimental pipelines, including GB18 for cancer cachexia and GB19 for systemic lupus erythematosus, alongside Phase III clinical updates for its long-acting GC and interferon inhalation solution, GB05.
The R&D Innovation Award recognized Kexing for its success in clinical translation and technological application. During the event, the company’s business development team participated in forums focused on the global commercialization of Chinese biopharmaceuticals. These sessions served as a venue to refine internationalization pathways, while a dedicated partner gathering on June 15 allowed the firm to strengthen its existing network of global collaborators.
Comments (0)
No comments yet. Be the first!